ArticleBMC infectious diseases2025
Pre-treatment blood cell counts and inflammatory markers predict the radiologic severity of post-tuberculosis lung disease.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Post-Tuberculosis Lung Disease: Clinicopathologic Insights, Diagnosis, Prevention, and Management.MedComm · 2026Review
- Circulating antibody signatures againstFrontiers in immunology · 2026Article
- Clinical Characteristics and Prognosis of Non-Small Cell Lung Cancer with Coexisting Pulmonary Tuberculosis: A Retrospective Matched-Cohort Study.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundPatients with pulmonary tuberculosis (TB) achieve microbiological cures following anti-TB treatment; however, post-tuberculosis lung disease (PTLD) persists in some. This study aimed to evaluate whether pre-treatment blood cell count indicators and inflammatory markers could predict the radiologic severity of PTLD.
methodsOverall, 169 patients with pulmonary TB diagnosed at Beijing Chest Hospital were prospectively enrolled. Baseline data were recorded and chest computed tomography (CT) images after the completion of anti-TB treatment were scored from 0 to 24 using a validated system. Patients were classified into mild and severe lung damage groups according to the median value of post-treatment chest CT score. Linear regression and logistic regression analyses were performed to assess the association between baseline inflammatory markers and post-treatment radiologic severity.
resultsThe overall mean age was 39.34 ± 15.37 years; 72.8% were men and 49.7% had a smoking history. The median CT score at the treatment end was 9 (interquartile range: 6–15). Significant positive correlations were observed between post-treatment CT scores and baseline erythrocyte sedimentation rate (ESR) (β = 0.040), high-sensitivity C-reactive protein (hs-CRP) (β = 0.030), white blood cell (WBC) count (β = 0.269), neutrophil percentage (β = 0.121) and count (β = 0.330), monocyte count (β = 4.169), and neutrophil-to-lymphocyte ratio (NLR) (β = 0.272). Negative correlations were identified with hemoglobin (Hb) (β = -0.070) and lymphocyte percentage (β = -0.138). Multivariable logistic regression confirmed the predictors.
conclusionPre-treatment ESR, hs-CRP, WBC count, Hb, neutrophil percentage and count, lymphocyte percentage, monocyte count and NLR are predictive of post-treatment radiologic severity. These findings highlight the potential for using readily available clinical markers to identify high-risk patients and guide personalized management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.